Abstract | Nucleic acid aptamers, often termed 'chemical antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability and lack of immunogenicity. In addition, many aptamers are internalized upon binding to cellular receptors, making them useful targeted delivery agents for small interfering RNAs (siRNAs), microRNAs and conventional drugs. However, several crucial factors have delayed the clinical translation of therapeutic aptamers, such as their inherent physicochemical characteristics and lack of safety data. This Review discusses these challenges, highlighting recent clinical developments and technological advances that have revived the impetus for this promising class of therapeutics.
Nucleic acid aptamers are short, single-stranded DNA (ssDNA) or RNA molecules that are selected for binding to a specific target. In 1990, several groups isolated the first RNA aptamers. In Tuerk and Gold's seminal report 1 , two high-affinity RNA ligands for the T4 DNA polymerase were enriched from an 8-nucleotide random region library using an in vitro procedure. Such a randomized library theoretically contains 4 N individual sequences that can be simultaneously tested in one tube. Candidate binding sequences are then subjected to iterative selection rounds to increase the population of high-affinity species, until they eventually dominate in the library. This procedure was thus named the systematic evolution of ligands by exponential enrichment (SELEX). Around the same time, Robertson and Joyce devised a similar in vitro selection method for the evolution of an RNA enzyme that specifically cleaved ssDNA 2 . Working independently, Ellington and Szostak also demonstrated the evolutionary power of this procedure 3 . Starting with a combinatorial pool of 10 13 different sequences, they successfully identified RNA molecules capable of specifically binding to small organic dyes. Ellington coined the term 'aptamer' , derived from the combination of the Latin word aptus ('to fit') and the Greek word meros ('part'). Together, these elegant studies led to a generalizable method for the in vitro generation of high-affinity aptamers that remains in common use today. To date, thousands of aptamers have been generated against a wide range of targets, including small metal ion and organic molecules, peptides, proteins, viruses, bacteria, whole cells and even targets within live animals.
Aptamers typically contain defined structures owing to their propensity to form complementary base pairs. They can fold into various secondary structures (for example, stem, loop, bugle, pseudoknot, G-quadruplex and kissing hairpin) 4 ; in turn, the collection of these secondary structures can form unique three-dimensional structures that are capable of specific molecular recognition of their cognate targets. These three-dimensional interactions, including hydrophobic and electrostatic interactions, hydrogen bonding, van der Waals forces, shape complementarity and base stacking, are essential for aptamer binding affinity and specificity 5 . Similarly to the way that antibodies bind to antigens, the specific three-dimensional interaction drives the formation of aptamer-target complexes 6 . This complexity confers comparable binding affinity and specificity, and even superior advantages over antibodies (BOX 1; TABLE 1). Aptamers are capable of distinguishing between closely related molecules, such as conformational isomers 7 , targets containing different functional groups 8, 9 or even an amino acid mutation 10 . However, the development of clinically effective therapeutic aptamers has lagged far behind that of therapeutic antibodies 11, 12 , which still dominate the global medicine marketplace 13 . For example, pegaptanib (Macugen; Pfizer/Eyetech), which is targeted against vascular endothelial growth factor (VEGF), is the only federally approved aptamer drug 14, 15 and has been superseded by VEGF-specific monoclonal antibodies such as bevacizumab (Avastin; Genentech) and ranibizumab (Lucentis; Genentech), which show improved therapeutic effects 16, 17 . In addition, the recent termination
Kissing hairpin
If two RNA stem-loops have complementary sequences in the loop regions, the two loops will base pair to form a kissing complex.
Macugen
Trade name of pegaptanib, a modified RNA aptamer that targets vascular endothelial growth factor (VEGF), and the first federally approved aptamer drug for the treatment of wet age-related macular degeneration.
of a phase III clinical trial of an anticoagulant aptamer against factor IXa exacerbated suspicion towards the therapeutic use of aptamers 18, 19 . Several crucial factors, such as their inherent physicochemical characteristics, a lack of medicinal chemistry support along with production costs, as well as a reluctance to break away from conventional approaches, have delayed and even suppressed the clinical translation and widespread distribution of therapeutic aptamers. Despite these limitations, recent progress in aptamer selection and formulation, as well as the lessons learned from nucleic acid clinical development, should encourage scientists to continue pursuit of therapeutic aptamers. Over the past decade, the demand for oligonucleotide products has driven global researchers and manufacturers to substantially improve existing approaches and technologies for oligonucleotide manufacturing (BOX 2) .
This Review frames the current challenges and potential of therapeutic aptamers, in particular RNA aptamers. We highlight more than 25 years' worth of technological advances and clinical development, as well as challenges and lessons learned, with a look towards the future of aptamer-based therapeutics.
The generation of RNA aptamers Principles of SELEX SELEX is a gold-standard methodology for generating various DNA or RNA aptamers [1] [2] [3] 20 . A selection cycle typically starts with a combinatorial DNA or RNA library containing a 20-60-nucleotide random region flanked by fixed primer regions at the 5ʹ and 3ʹ ends. An initial, unselected library theoretically consists of up to 10 15 unique sequences (1-2 nmol of library), which can provide enough structural diversity to identify highaffinity binders. After iterative selection cycles consisting of binding, partitioning, recovery and re-amplification steps, specific sequences -aptamers -are enriched and dominate the population of library species. The final product is sensitive to the selection environment, which is a combination of experimental conditions (for example, the ratio of library to target, buffer components, ion strength, pH, and binding temperature or time) and target-inherent properties (for example, pI, charge and hydrophilicity). Together, these variables contribute specific selection stringency, consequently affecting the affinity and function of the enriched aptamers.
There are some differences between the selection of RNA and DNA aptamers. In the case of DNA SELEX, a library is incubated with the target, and the bound sequences are recovered following re-amplification by PCR. In the case of RNA aptamers, they must first be reverse-transcribed into double-stranded DNA to enable subsequent RNA transcription. For DNA aptamers, the resulting double-stranded DNA library is subjected to strand separation to produce a new ssDNA library for the next selection cycle. RNA SELEX generally involves in vitro transcription. DNA and RNA aptamers are functionally similar, but each has its own benefits. DNA aptamers are inherently more stable and the related manufacturing costs are lower. RNA aptamers typically have more diverse three-dimensional conformations, and stronger intra-strand RNA-RNA interactions, which probably increase binding affinity and specificity 21 .
Purified-protein-based SELEX
In a purified-protein-based SELEX procedure 22 (FIG. 1a) , one of the most important steps is selection partitioning -the separation of target-bound sequences from unbound sequences in the library. Various solid-phase matrix-based segmentation strategies have been used 23 , including nitrocellulose membrane, affinity column/ resin chromatography, magnetic beads and chip-based segmentation. For example, nitrocellulose membrane is a popular matrix used in SELEX owing to its high protein-binding affinity over nucleic acids, whereas nylon membrane favours binding of negatively charged oligonucleotides for blotting applications with nucleic acids, such as a double filter assay. When the mixture of the random library and target protein is passed through a nitrocellulose membrane filter, size exclusivity ensures that larger aptamer-protein complexes are retained on the membrane while small, unbound nucleic acid molecules with weak affinity to the membrane freely flow through. With magnetic beads, the target protein is first immobilized on the surface of the beads, which are then incubated with the random library; the resulting mixture is subjected to magnetic precipitation to recover bound sequences. During the RNA SELEX experiment, chemically modified nucleoside triphosphate derivatives (2ʹ-aminopyridmidine or 2ʹ-fluoropyrimidine) are routinely incorporated into RNA to improve RNase resistance via in vitro transcription 24, 25 . Purified-proteinbased SELEX has successfully generated many highaffinity aptamers and has several advantages: the selection
Box 1 | Nucleic acid aptamers versus protein antibodies
Aptamers possess many attractive features. For example, compared with bulky antibodies (150-180 kDa, ~15 nm in diameter), aptamers have a smaller size (6-30 kDa, ~2 nm in diameter) and flexible structure, allowing them to bind to smaller targets or some hidden binding domains that are inaccessible for the larger antibodies. Larger antibodies may exhibit limited tissue penetration, particularly in solid tumours, which may compromise their therapeutic efficacy. Although their small size makes aptamers susceptible to kidney filtration and a short circulation time in vivo, rational chemical modification and conjugation can improve their pharmacokinetic profile and prolong half-life. Compared with the lengthy, laborious and expensive in vivo screening involved in antibody generation, aptamers can be isolated within days via a cost-efficient in vitro selection procedure. Because the immune response results in antibody production, its targets must trigger a strong reaction from the immune system. In principle, aptamers can be selected against an infinite spectrum of targets, including toxic and non-immunogenic molecules that cannot be recognized by antibodies. Furthermore, aptamers have many manufacturing benefits, particularly for production under current good manufacturing practice (cGMP) standards. The production of antibodies involves animals and many different cell colonies, which offer opportunities for contamination and high batch-to-batch variation. By contrast, aptamers are manufactured in a completely in vitro setting, relying on a chemical synthesis procedure with no or lower risk of contamination. Moreover, the propensity of aptamers to form complementary base pairs confers additional benefits, in that the function of aptamers can be modulated in vivo using antidote oligonucleotides, which disrupt aptamer function by base pairing with the active motifs of the aptamers. In this way, a rationally designed antidote may allow precise control of the therapeutic effect. A comprehensive comparison of the advantages and disadvantages of nucleic acid aptamers versus antibodies is shown in • Slower • Long circulation time (up to 1 month)
Patents and distribution
• Exclusive patents in SELEX technology • Limited initial distribution
• Expired protection or no early patents • More widespread distribution
Development and market
• The development pathway is less explored • Insufficient education and investment (R&D support)
• Commercialization has focused on diagnostic-based aptamer products
• Well-developed infrastructure • Abundant support from finance and education • Rapid and sustained increase in drug market share cGMP, current good manufacturing practice; nt, nucleotide; SELEX, systematic evolution of ligands by exponential enrichment.
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(VEGF). A secreted protein that is capable of inducing angiogenesis and increasing vascular permeability and inflammation.
Bevacizumab
Trade name Avastin; a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), and an approved antibody drug for the treatment of certain metastatic cancers and eye diseases.
Ranibizumab
Trade name Lucentis; a monoclonal antibody fragment created from bevacizumab, and an approved antibody drug for the treatment of age-related macular degeneration.
Hairpin
A complementary region of nucleic acid that can form Watson-Crick base pairs and generally results in a stemloop structure that resembles a hairpin.
steps can be performed in a test tube without involving sophisticated technology, the selection conditions or evolution pressures are easily tunable, and the targets can be either intracellular or extracellular proteins 26 . Although protein-based SELEX may be applied to purified proteins, protein targets on the surface of whole cells or even proteins within live animals, it is not applicable for unknown proteins, insoluble proteins or proteins that only function in the native conformation or a multiprotein complex 27 . In some cases, the aptamers generated via purified-protein-based SELEX fail to recognize the target protein on the cell surface [28] [29] [30] .
Whole-cell-based SELEX
Whole-cell-based SELEX offers a reasonable alternative to overcome some of the limitations of purified-proteinbased SELEX. It allows identification of specific aptamers that are capable of selectively binding to the target protein in its native conformation or capable of binding to the original glycosylation pattern of the extracellular domain, and even internalizing into the target cells [31] [32] [33] . The basis of the selection procedure relies on the differences between the target cell population that expresses the target of interest and a negative cell population that does not. In particular, it can be applied to uncharacterized target proteins, for which there is no prior knowledge of their properties and structural features 34, 35 . This advantage allows whole-cell-based SELEX to be exploited as a promising tool for biomarker discovery 36 . There are various approaches to produce negative cells (lacking targeting protein) or positive cells (overexpressing target protein). For example, gBlocks gene fragments can be used to create the corresponding cDNA containing the desired target sequence. Alternatively, CRISPRCas9 technology can be applied with positive cells to knock out the target gene, thereby producing negative cells for counter-selection.
A whole-cell-based SELEX experiment (FIG. 1b) typically involves counter selection and positive selection. The selection is performed with intact, living cells, thereby ensuring that target proteins on the cell surface keep their active conformation and functionality throughout the selection process. One caveat is that nucleic acids have a propensity for binding to dead cells in a nonspecific manner, which can impede effective enrichment of target-specific sequences or even result in SELEX failure 37 . Modification of the process to ensure careful recovery of healthy cells (for example, using fluorescence-activated cell sorting (FACS) technology 38 ) expressing a high level of active receptors is critical for selection success.
Live-animal-based SELEX
As aptamers selected in vitro may not necessarily function in vivo 11, 39 , a live-animal-based SELEX procedure was developed to generate tissue-penetrating aptamers directly within a living animal model of the target disease or condition (FIG. 1c) . Researchers administer the RNA library intravenously to the animal, harvest the tissue or organ of pathological interest and extract the bound sequences. The recovered RNA sequences are then re-amplified to make a new RNA library for the next selection cycle. This technique has been used to identify 2ʹ-fluoropyrimidine-modified RNA aptamers in an animal model of intrahepatic colorectal cancer meta stases 40 . The resulting nuclease-resistant RNAs specifically localize to targets within intrahepatic tumour deposits. In addition, a 2ʹ-fluoropyrimidine-modified RNA library has been administered to wild-type mice, and their brains harvested for the recovery of aptamers that bind to brain capillary endothelia and penetrate into the parenchyma 41 . These examples demonstrate the efficacy of live-animalbased SELEX as a direct method for generating RNA aptamers that are suitable for use in vivo.
Recent advances in SELEX technology
Although classic SELEX has proved to be a powerful and effective aptamer-selection procedure, intensive efforts have been made to streamline the methodology and optimize selection efficiency 23, 42 . Several important advances have improved the overall performance of SELEX, such as efficient partitioning and recovery, accurate amplification and global analysis of sequencing data. For example, introduction of a negative-SELEX eliminates nonspecific sequences that bind to environmental components 43 , especially to a solid-phase matrix used for partitioning support or target immobilization. The resultant aptamers exhibit up to tenfold higher binding affinity compared with those generated from SELEX The advent of SELEX (systematic evolution of ligands by exponential enrichment) technology has generated a flourishing area of aptamer research for a wide range of applications, including diagnostics, biosensor technologies, affinity isolation, biomarker discovery and, in particular, targeted therapeutics. Although antibody-based products still substantially dominate the global marketplace in diagnostics and therapeutics, there are a handful of biotechnology and pharmaceutical companies actively struggling against those conventional products.
The demand for oligonucleotide products has driven global researchers and manufacturers to devote themselves to substantial improvements in approaches and technologies for oligonucleotide manufacturing (TABLE 3) . Synthesis can be completed in 2 days or up to 2 weeks. RNA aptamers with special modifications and conjugations can be custom-ordered from manufacturers such as TriLink or IDT. However, the manufacturing cost of longer RNAs (>60 nucleotides) is typically higher than that of short RNAs because of increased difficulties in synthesis and purification. For example, PAGE (polyacrylamide gel electrophoresis)-purified 2′-fluoropyrimidine-modified RNA (which is 100 nucleotides in length) generally costs $2,500 per milligram (in milligram scale from TriLink). In addition, SomaLogic, a powerhouse in the aptamer-based diagnostic market, has now generated SOMAmer (slow off-rate modified aptamer) reagents for more than 1,300 different protein targets that are crucial for normal and disease biology. The company is exploiting a series of SOMAmer associated array platforms, such as SOMAscan and SOMApanel, for proteomic and diagnostic applications. NOXXON has exclusive licences for the SELEX process in the discovery, manufacturing and application of Spiegelmers, and energetically discovers and develops Spiegelmer therapeutics using the in-house discovery platform. To date, more than ten Spiegelmers have been generated against various diseased-related targets, including three in clinical trials and four in the preclinical pipeline. Currently, diagnostic applications account for the largest aptamer market share, but therapeutic application of aptamers is estimated to grow rapidly as a result of increasing research activities and commercial investment.
Emulsion PCR (ePCR) or droplet digital PCR (ddPCR)
Systems that compartmentalize and miniaturize PCR by generating a water-in-oil emulsion containing numerous droplets, which creates a local homogeneous amplification microenvironment. 
High-throughput sequencing (HTS)
.
Spiegelmers
Trade name of the l-ribonucleic acid aptamers developed by NOXXON Pharma; mirror-image RNAs built from natural l-ribose units.
without negative selection. A counter-SELEX excludes sequences recognizing other targets by using analogue targets, thus increasing the selectivity of the aptamers 7, 8 . In addition, specialized partitioning technologies, such as capillary electrophoresis (CE) [44] [45] [46] , atomic force microscopy (AFM) 47, 48 , flow cytometry 38, 49 , microfluidics 50, 51 and biacore surface plasmon resonance (SPR) 52 , have been successfully adopted into the classic SELEX procedure to accelerate high-affinity aptamer identification.
Previous studies have revealed that conventional PCR may limit amplification of a heterogeneous library owing to factors such as low efficiency and the formation of nonspecific product-product hybridizations and primer dimers [53] [54] [55] . In conventional PCR-driven SELEX, non specific byproducts appear as early as the 15th amplification cycle, and all of the expected products are completely converted to by-products by the 30th cycle. With the increase in PCR cycles and iterative selection rounds, excessive accumulation of amplification artefacts hampers the enrichment of high-affinity aptamers, and may even cause selection failure 54 . Recently, emulsion PCR (ePCR) or droplet digital PCR (ddPCR) have been incorporated into the selection protocol to reduce the propagation of by-products and to avoid PCR bias 45, [56] [57] [58] . These modified techniques preserve library diversity and prevent the loss of highly structural aptamer sequences that are difficult to amplify in a conventional PCR system.
In a traditional SELEX, the final enriched library is cloned and subjected to classic Sanger sequencing analysis for the identification of individual aptamer sequences. The entire process is considered to operate within a 'black box' until specific aptamers are identified at the final round. However, high-throughput sequencing (HTS) technology has revolutionized the selection of aptamers by making the selection process visible with each round of selection. HTS and bioinformatics analysis combined with SELEX (HT-SELEX) not only facilitates the rapid identification of high-affinity aptamers but also reveals a comprehensive landscape for the molecular evolution events [59] [60] [61] . Millions of sequence reads can be processed from each selection cycle, thus providing insight into the entire process, including primary sequences, total reads, nucleotide composition, frequency and rate of molecular enrichment 62, 63 . Because HT-SELEX allows quantitative assessment of the dynamic changes in the library composition throughout selection cycles, it is capable of identifying high-affinity aptamers at a much earlier round, which is more cost-efficient and avoids the potential PCR bias associated with over-selection. Global analysis of large sequence data sets by robust bioinformatics tools can further facilitate high-throughput characterization of aptamers, including structure prediction, binding affinity and/or specificity, functional properties and aptamer-target interactions 59 .
Challenges in aptamer-based therapeutics As they are nucleic acid biopolymers, the in vivo therapeutic potency of aptamers is crucially limited by their inherent physicochemical characteristics. These characteristics can affect pharmacokinetic properties resulting in metabolic instability, rapid renal filtration, rapid distribution from the plasma compartment into the tissues (for example, the liver or spleen), nonspecific immune activation and polyanionic effects. Various chemical modifications and conjugations have therefore been developed to improve the pharmacokinetic properties of aptamer-based therapeutics 64 .
Nuclease degradation
Unmodified aptamers are susceptible to nuclease-mediated degradation that causes very short half-lives in vivo (less than 10 minutes) 39 . Most aptamers in clinical studies are chemically modified (TABLE 2) by replacing the 2ʹ position with a fluoro (F), amino (NH 2 ) or O-methyl (OCH 3 ) group, and by capping the 3ʹ end with inverted thymidine to increase nuclease resistance while also enhancing binding affinity. In practice, two different strategies are applied to incorporate modified nucleotides into aptamers: in-SELEX and post-SELEX. In the in-SELEX strategy, aptamers with the desired modifications are directly isolated from a DNA or an RNA library containing modified nucleotides that are compatible with DNA or RNA polymerases 65, 66 . However, only a limited number of modifications are possible with this method. So far, 2ʹ-aminopyrimidines 67 , 2ʹ-fluoropyrimidines 68 , 2ʹ-Omethyl nucleotides 69 and locked nucleic acids (LNA) 70, 71 have been successfully incorporated into the SELEX protocol. In addition, a method called SOMAmer (slow off-rate modified aptamer) selection 72, 73 , developed by SomaLogic, uses modified deoxyuracil carrying hydrophobic functional groups at the C5 position, which is well tolerated by DNA polymerase
. Three clinically evaluated aptamers are Spiegelmers, L-form RNA aptamers that are chiral inversions of their natural D-forms. As Spiegelmers cannot be recognized by nucleases, they display excellent in vivo biostability compared with their natural d-form nucleic acids 74 . However, Spiegelmer technology requires obtaining the enantiomer of the target of interest for SELEX, thereby limiting its practical utility for some biological macromolecules 75 . In post-SELEX strategies, modifications at various positions (for example, the base, 2ʹ-position, sugar ring or phosphate group) are introduced in pre-selected aptamers during solid-phase chemical synthesis. Multiple modifications are sometimes applied in combination for optimal performance. As the affinity and/or specificity and function of an aptamer are sensitive to its structure, post-SELEX modification may affect the inherent properties and folding structures of the original aptamers, thereby compromising binding affinity. Therefore, it is necessary to precisely tailor modifications for the desired functions 76 . Unfortunately, universal rules are not available for all aptamers, and laborious evaluation and optimization are often needed 77 .
Renal filtration
The average diameter of aptamers with a mass of 6-30 kDa is less than 5 nm (REF. 78 ). When non-formulated aptamers are administered into the bloodstream, even using stabilizing backbone modifications, small aptamers are subjected to rapid excretion through renal filtration. To overcome renal filtration and extend circulation time, 
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A modified RNA aptamer RB006 (pegnivacogin) and an antidote oligonucleotide RB007 (anivamersen); the first aptamer-based anticoagulation system in clinical trials.
aptamers are generally formulated with a bulky moiety, such as high-molecular-mass polyethyl ene glycol (PEG) 69 , cholesterol 79, 80 , proteins 81, 82 , lipo somes 83 , organic or inorganic nanomaterials 10, 84 , or they are multimerized [85] [86] [87] to create a multivalent molecule with a mass above the cut-off threshold for the renal glomerulus (30-50 kDa). PEG is a well-studied, hydrophilic biomaterial that decreases aggregation and increases the solubility of the conjugates. PEG has been widely used in many US Food and Drug Administration (FDA)-approved formulations to prolong circulation half-life and improve the in vivo bioavailability of therapeutic aptamers following intravenous administration. For example, pegylation of Macugen (see below) increased its half-life to 9.3 hours and 12 hours in plasma after intravenous injection or subcutaneous injection, respectively, and even to 94 hours in vitreous humour 88, 89 . Compared with a monovalent aptamer, rationally designed multivalent aptamers have shown an improved overall performance, including binding affinity and specificity, biological function and circulation time. For example, tetrameric aptamer conjugates with increased retention in circulation and improved pharmacokinetic properties have been generated 90 .
Toxicity
Toxicological information regarding aptamers in humans is very limited 91, 92 . Although aptamer-related adverse events are rare in clinical evaluations to date, potential toxicities may arise from polyanionic effects, unexpected tissue accumulation, intensive chemical modification or conjugation, and nonspecific immune activation, in particular with continuous or repeated administration of aptamer therapeutics [93] [94] [95] . Highly negatively charged molecules (for example, nucleic acids) are prone to nonspecific binding to blood proteins, which may result in high uptake by non-target tissues and organs, thereby causing unwanted side effects and reducing therapeutic efficacy 96, 97 . Chemical modifications have proved to be a double-edged sword, as unnatural nucleotides may cause chemical toxic effects or become immunogenic. For example, severe hepatotoxicity was observed in LNA-modified nucleic acids 98 , and 2ʹ-fluoropyridimine-modified RNAs differentially controlled the activation of pattern recognition receptors 76 . Thus, chemical modifications should be used cautiously, according to the desired therapeutic application of the aptamers. Adverse responses can also be associated with the formulation of therapeutic aptamers. For example, serious allergic responses to the PEG group, because of the presence of pre-existing antibodies against PEG, have been reported in the phase III study of Regado Biosciences' aptamer-based anticoagulation system, the REG1 system (see below), raising safety concerns about the use of pegylated agents in patients with acute illnesses 18, 99 . Highly lipophilic molecules often result in nonspecific liver uptake, which may trigger potential hepatotoxicity 100 . Prudent formulations or administration routines are therefore necessary for improved development of aptamer therapeutics.
Recent progress in aptamer-based therapeutics
Aptamer-based therapeutics typically exploit one of three strategies: an aptamer can serve as an antagonist to block the interaction of disease-associated targets, such as protein-protein or receptor-ligand interactions; an aptamer can serve as an agonist to activate the function of target receptors; or a cell-type-specific aptamer can serve as a carrier to deliver other therapeutic agents to the target cells or tissue. This topic has been well reviewed elsewhere 11, 26, 101 .
Aptamers as antagonists
An inhibitory aptamer that can disrupt the function of a pathological target protein can be used directly as a therapeutic antagonist. All aptamers currently in clinical trials fall into this category (as discussed in detail below). Numerous groups have developed aptamers against therapeutically relevant targets associated with several human diseases, including ocular disorders, bleeding disorders, cancer, cardiovascular disease, autoimmune disease, degenerative neurological disease and infectious disease 26, 102 . In addition, artificial RNA sequences that mimic natural RNAs have been evolved using the in vitro SELEX process. For example, an RNA decoy is designed to compete with the natural RNA sequence that is the target of an RNA-binding protein, which sequesters the interaction of the natural RNA sequence and its target protein 103 . In HIV-1, the transactivator Tat protein binds to specific regulatory elements (transactivation responsive element TAR) in the HIV-1 long-terminal repeats (LTRs) and regulates viral transcription. Synthetic TAR RNA decoys that mimic the apical loop of the TAR sequence showed high affinity to Tat protein, inhibited HIV RNA transcription and thus reduced viral replication [104] [105] [106] . Despite their exquisite affinity and specificity, the therapeutic potential of inhibitory aptamers may not be fully achieved because of their suboptimal design or formulation. The biodistribution of aptamer conjugates varies with their actual size, charge and other physical Figure 1 | The generation of RNA aptamers. A commercially obtained single-stranded DNA (ssDNA) pool is used as an initial template for generating a double-stranded DNA (dsDNA) library by PCR and is subsequently converted into a corresponding RNA library via in vitro transcription for the first selection cycle. a | Purified protein-based SELEX (systematic evolution of ligands by exponential enrichment) uses four key steps. In step 1, the RNA library is incubated with the target protein. In step 2, the bound species are isolated from the unbound sequences through various partitioning strategies. In step 3, target-bound sequences are recovered. In step 4, the sequences are subjected to re-amplification (reverse transcription (RT), PCR and in vitro transcription) into a new RNA library for the next selection cycle. Through these iterative rounds, specific aptamers are enriched and identified by sequencing analysis. b | Whole -cell -based SELEX consists of four main steps.
Step 1 involves counter selection by incubating the RNA library with negative cells that do not express the target protein.
Step 2 involves positive selection by incubating recovered unbound sequences with positive cells expressing the target protein.
Step 3 involves recovery of target-bound sequences.
Step 4 involves re-amplification of recovered species and generation of a new RNA pool for the next selection round. c | Live-animal-based SELEX. After intravenous administration and circulation of an RNA library in the animal model (step 1), the tissue or organ of pathological interest is harvested (step 2) and the bound sequences are extracted (step 3). Subsequently, the recovered RNA sequences are re-amplified to make a new RNA library for the next selection cycle (step 4). characteristics. Rational design and formation are crucial. Recent progress that has been made to improve the design or formulation of aptamers is highlighted below.
▶
Formulation with an inert antibody. The VEGFtargeted aptamer pegaptanib, which is approved for use in ophthalmology 107 (see below), was originally designed for use in cancer therapy. In vivo evaluation in a tumour xenograft model indicated its inhibitory effect on VEGF-induced vascular permeability and tumour growth 108 . However, its anticancer efficacy did not meet expectations in some early preclinical studies. To improve the in vivo pharmacokinetics of the aptamer, an aptamer-antibody hybrid complex was recently generated using a cotinine-specific antibody and the cotinine-conjugated pegaptanib aptamer 82 . This complex distributed widely throughout the tumour tissue and exhibited a prolonged half-life (8.2 hours) in serum. In an A549-xenograft mouse model, systemic administration of the pegaptanib-antibody complex inhibited tumour angiogenesis owing to enhanced tumour tissue penetration, consequently decreasing tumour growth to a degree comparable to that observed with bevacizumab. This proof-of-principle study may represent a new formulation strategy for the use of aptamer-antibody complexes in targeted cancer therapy.
Formulation with cholesterol. Although cholesterol conjugation has been reported to reduce renal filtration and increase hepatic cell uptake via receptor-mediated endocytosis, analyses of the pharmacokinetics and administration routes for cholesterol-conjugated aptamers are limited. Recently, the safety and pharmacokinetic profile of a cholesterol-conjugated RNA aptamer against the hepatitis C virus (HCV) NS5B protein was assessed in a preclinical study 80 . Systemic administration of the cholesterol-conjugated RNA aptamer was well tolerated, without any abnormalities in wild-type BALB/c mice, and showed a twofold extended half-life compared to the non-conjugated aptamer. Intravenous administration demonstrated a longer (five to six times) circulation half-life and higher (two to three times) drug exposure than intraperitoneal administration, suggesting that the intravenous route may be more suitable for cholesterolconjugated aptamers.
Formulation with nanoparticles.
A single amino acid substitution (R175H) in tumour suppressor p53 results in inactivation of wild-type p53, which affects several cancer-associated pathways 109 . A contrast screening SELEX strategy was applied to select an exquisitely sensitive RNA aptamer capable of distinguishing p53-R175H from wild-type p53 protein 10 . The aptamer inhibited cell migration and invasion in human lung cancer cells harbouring p53-R75H. To limit degradation, the aptamer was formulated with sheddable nanoparticles derived from pegylated polyethylenimine. Following administration to a tumour xenograft model either by subcutaneous injection or tail vein intravenous injection, the nanoparticle-conjugated aptamer inhibited tumour growth.
Formulation with pluronic gel. Migration and proliferation of vascular smooth muscle cells (VSMCs) have a key role in the development of cardiovascular disease. Such disease is generally treated with antiproliferative or antimigratory drugs (for example, paclitaxel) to directly block VSMC activation 110 . Through a cell-based HT-SELEX strategy, a nuclease-resistant RNA aptamer was identified to preferentially target VSMCs over endothelial cells and nonvascular myocytes, and specifically inhibited VSMC migration 111 . In preclinical assessments, this aptamer exhibited a half-life of ~300 hours in human serum, with no pathological immune response in human peripheral blood mononuclear cells. When the RNA aptamer was formulated with pluronic gel, a biphasic micellar system for transdermal drug delivery, and applied around the carotid artery in a ligation mouse model of vascular injury, neointimal formation was inhibited to levels similar to those observed with paclitaxel, the current standard of care. This confirmed effective delivery of the RNA aptamer to the vessel wall as a result of pluronic gel formation. 
AMD, age-related macular degeneration; C5, complement component 5; CCL2, chemokine C-C motif ligand 2; CXCL12, chemokine C-X-C motif ligand 12; dT, deoxythymidine; nt, nucleotide; PDGF, platelet-derived growth factor; PEG, polyethylene glycol; TFPI, tissue factor pathway inhibitor; VEGF 165 , vascular endothelial growth factor isoform 165. Formulation as a multimer. Multiple anticoagulant aptamers target prothrombin and/or thrombin or activated coagulation factor X (FXa) (see below) 112 . Although no individual aptamer has yet rivalled heparin, a widely used injectable anticoagulant 113 , a combination of multiple aptamers targeting different coagulation enzymes can be as potent as heparin for the prevention of fibrin clot formation 114 . Unfortunately, a cocktail formulation of multiple aptamers substantially increases the complexity and cost of clinical development 115 . Any unapproved individual aptamer, as well as the combination, have to be subjected to preclinical and phase I studies to ensure the safety of each ingredient. Instead, multimerization of individual aptamers into a single unit may offer an alternative strategy. Recently, by using a single bivalent aptamer that simultaneously targets two different coagulation cascade proteins, heparin-level anticoagulation potency was observed in human blood 86 . Notably, a single antidote rapidly reversed the anticoagulation effect mediated by the bivalent aptamer in a dose-dependent manner.
Aptamers as agonists
To date, only a few aptamers have been developed to function as therapeutic agonists. This includes RNA aptamers targeting human epidermal growth factor receptor 3 (HER3; also known as ERBB3) 116 , OX40 (also known as CD134) 117, 118 , 4-1BB (also known as CD137) 119 , CD40 (REF. 120 ), CD28 (REF. 121 ) and DNA aptamers targeting human VEGF receptor 2 (REF. 122 ) and the insulin receptor 123 . Several of the RNA aptamers targeting immune co-stimulatory receptors (CD28, CD40, OX40 and 4-1BB) have been engineered into multimeric versions to act as receptor agonists for improved cancer immunotherapy 124 . The efficient co-stimulation on the surface of antigen-presenting cells or T cells induced by the interaction of a co-stimulatory receptor and its ligand has an important role in improving antitumor immunity 125 . 4-1BB RNA aptamer. By using a complementary linker, two monomeric 4-1BB aptamers were converted to a bivalent form 119 (FIG. 2a) . Although both monovalent and bivalent aptamer forms bound to 4-1BB-expressing cells, only the bivalent aptamer was capable of costimulating T cell activation and promoting tumour rejection in vivo, with an efficiency comparable to that of a previously described 4-1BB-specific antibody. As co-stimulatory activity is dependent on the spatial arrangement and distance of the linked aptamers, rational design is crucial. To trigger crosslinking of the 4-1BB receptor, the distance between the aptamers was formulated to be 5-18 nm (the approximate distance between the two variable domains of the 4-1BB-specific antibody). A 21-bp double-stranded linker provided a distance of 7.1 nm between the two 4-1BB aptamers, and allowed the correct orientation for binding to a pair of 4-1BB receptors. This study provides a preliminary example of multivalent aptamers with agonistic function for cancer immunotherapy.
OX40 RNA aptamer. The crystal structure of the OX40 receptor-ligand complex revealed multiple binding sites for its ligand 126 , suggesting that an OX40 aptamer would require a multivalent form to effectively stimulate OX40 function. Two copies of an anti-murine OX40 aptamer were assembled onto a flexible DNA oligonucleotide-based molecular scaffold 117 (FIG. 2b) . The resulting bivalent aptamer activated the OX40 receptor on primed T cells in vitro, and systemic administration of this bivalent aptamer significantly enhanced antitumour responses generated by a dendritic cell-based vaccine in mice. Recently, two anti-human OX40 RNA aptamers containing a biotin group at the 5ʹ end were formulated into a bivalent aptamer via a streptavidin linker, which stimulated OX40 on human T cells and enhanced cell proliferation as well as interferon-γ (IFNγ) production 118 . CD28 RNA aptamer. Two RNA aptamers that specifically bind to murine CD28 have been isolated from a 2ʹ-fluoropyrimidine-modified RNA library, and their monomeric and dimerized forms have shown distinct behaviours 121 . In the monomeric form, one aptamer (CD28Apt2) functioned as an antagonist to block the interaction of CD28 with its main ligand, B7.2, and preclude co-stimulatory signalling; by contrast, the monomeric form of another aptamer (CD28Apt7) was inactive. When the two aptamers were converted into bivalent forms, both of them functioned as an agonist, providing an artificial co-stimulatory signal. Dimeric agonistic aptamers were engineered by either using a 21-bp double-stranded linker to fuse the two individual aptamers or by transcribing the dimeric aptamer as a single strand without any extra linker. Of the four dimeric aptamers, the CD28Apt7 dimer without the extra linker significantly improved the co-stimulatory properties and surpassed the agonistic effect of a CD28-specific antibody. When co-administered with an idiotype vaccine, the CD28 agonistic aptamer also enhanced the cellular immune response in vivo and prolonged survival Nonsense-mediated mRNA decay (NMD). A translation-coupled mechanism that degrades mRNA containing premature translation-termination codons (PTCs). 
Small interfering RNAs
AntimiRs
Synthetic oligonucleotides designed to neutralize microRNA function.
RNA interference
(RNAi). A highly conserved endogenous process for post-transcriptional regulation of gene silencing that is triggered by small regulatory RNAs, including small interfering RNAs.
gp120
An HIV-1 envelope glycoprotein. gp120 is exposed on the surface of virus particles and the plasma membrane of HIV-1-infected cells. The interaction of HIV-1 gp120 with the cellular CD4 receptor is a crucial step in the entry of HIV into T cells.
of lymphoma-bearing mice. This study demonstrates that aptamers may be rationally engineered to achieve a desired function, such as inhibiting protein-receptor interactions as antagonists or achieving co-stimulation as agonists, depending on the therapeutic need. Unlike aptamers, to date no therapeutic antibody has demonstrated such dual functionality. CD40 RNA aptamer. Most recently, two 2ʹ-fluoropyrimidine-modified RNA aptamers against the murine CD40 receptor were isolated 120 . CD40 aptamers were engineered into three constructs with different functions. The agonistic bivalent aptamer caused proliferation and activation of B lymphocytes, and accelerated recovery of bone marrow aplasia, whereas the antagonistic monovalent aptamer reduced B cell lymphoma proliferation and improved overall survival in BALB/c mice. Moreover, the agonistic bivalent aptamer was conjugated with a short hairpin RNA (shRNA) targeting SMG1, a serine/threonine kinase that is essential for nonsense-mediated mRNA decay (NMD) initiation. The resulting agonistic aptamer-shRNA chimaera inhibited NMD and improved tumour infiltration and overall survival in vivo.
Aptamers as delivery agents
In addition to their utility as stand-alone therapeutics, aptamers may be used as escorts for another therapeutic. Various cell-type-specific aptamers have been conjugated with therapeutic agents (for example, small interfering RNAs (siRNAs), microRNAs (mi RNAs), antimiRs, therapeutic aptamers, chemotherapeutics or toxins), or delivery vehicles (for example, organic or inorganic nanocarriers) for targeted delivery in a cell-type-specific manner. By taking advantage of the high affinity and specificity of aptamers, therapeutic compounds can be targeted to the desired cells or tissues, thereby improving their local concentration and therapeutic efficacy. A full list of cell-type-specific aptamers has been published 101 . Several representative aptamer-mediated delivery systems are illustrated below.
Aptamer-therapeutic oligonucleotide conjugates.
An initial example of an aptamer-therapeutic oligonucleotide conjugate is a 2ʹ-fluoropyrimidine-modified aptamer targeting human prostate-specific membrane antigen (PSMA), a transmembrane protein that is highly expressed in human prostate cancer and the vascular endothelium 127 . Through either covalent fusion or physical assembly, PSMA aptamers have been successfully conjugated with various therapeutic oligonucleotides to achieve targeted delivery. In a proof-of-concept study, covalent PSMA aptamer-siRNA chimaeras were developed 128 (FIG. 3a) , which selectively internalized into PSMA-expressing cells and effectively suppressed the targeted tumour survival genes, such as Polo-like kinase 1 (PLK1) and B cell lymphoma 2 (BCL2), in cultured cells as well as in animal models. Subsequent efforts further optimized the design through rational modifications of both aptamer and siRNA portions 129 . The resulting second-generation chimeric RNA aptamer demonstrated improved circulation and bioavailability in vivo, resulting in significant regression of PSMAexpressing tumours following systemic administration. Using the same strategy, anti-NMD factor siRNAs (SMG1 and up-frameshift suppressor 2 homologue (UPF2)) were conjugated with the PSMA aptamer, and inhibited tumour growth after systemic administration in both subcutaneous and metastatic tumour models 130 . Several variants have also been developed to simplify formulation or enhance cargo-loading capability. For example, the PSMA aptamer was covalently fused with an shRNA against DNA-activated protein kinase (FIG. 3b) , which resulted in selective RNA interference (RNAi) activity in PSMA-positive cells 131 . When combined with ionizing radiation, the aptamer-shRNA chimaeras improved the response of the PSMA-positive tumours to ionizing radiation. Bivalent aptamer-siRNA chimaeras have also been generated to increase binding affinity and cellular uptake, and to improve the inhibitory effect of siRNAs 132 . PSMA aptamers can be non-covalently conjugated to therapeutic oligonucleotides via a molecular platform or bridge. For example, two copies of biotinylated PSMA aptamers and biotinylated siRNAs have been physically assembled on a streptavidin connector 133 (FIG. 3c) . The resulting multivalent conjugate selectively delivered siRNA into PSMA-positive cells, and induced specific RNAi activity.
The PSMA aptamer can also be used to deliver therapeutic aptamers. The aforementioned bivalent 4-1BB aptamer and the PSMA aptamer have been tethered together through a complementary linker sequence, consequently resulting in a tumour-targeting co-stimulatory aptamer conjugate 134 (FIG. 3d) . When administered systemically, this bispecific conjugate significantly inhibited tumour growth and led to more effective tumour rejection in vivo than that achieved using 4-1BB antibodies.
Another example of an aptamer-therapeutic oligonucleotide conjugate has been developed in the context of HIV. In HIV, the envelope glycoprotein gp120 interacts with the host cell receptor CD4 and co-receptor CCR5 during viral entry. Our own group has developed several novel dual-inhibitory gp120 aptamer-siRNA conjugates, in which both the aptamer and the siRNA portions have potent anti-HIV activities 135, 136 . The 2ʹ-fluoropyrimidinemodified gp120 aptamer has dual functions: first, as an HIV-1 inhibitor that blocks the interaction of gp120 and the CD4 receptor; and second, as a cell-type-specific delivery agent for an siRNA. One design is a covalent aptamer-siRNA chimaera (FIG. 3a) , and the other is a noncovalent aptamer-stick-siRNA conjugate (FIG. 3e) . In the latter design, the aptamer and siRNA portions are hybridized using a GC-rich sticky bridge sequence, which provides a facile approach to conjugating various aptamers or siRNAs for combination treatment. The gp120 RNA aptamer specifically delivered anti-HIV siRNA into HIV-1 infected cells and inhibited HIV-1 activity in vitro. Systemic administration of these aptamer-siRNA conjugates suppressed HIV-1 replication by several orders of magnitude and prevented CD4 + T cell depletion in a humanized mouse model of HIV. The siRNA delivered by the gp120 aptamer was processed by Dicer and triggered specific RNAi activity 137, 138 . Such combinations of therapeutic siRNAs and aptamers may provide more effective treatment of highly mutated viral infection by simultaneously inhibiting multiple different targets.
Cell-type-specific RNA aptamers can similarly be used to deliver antimiR oligonucleotides 139, 140 (FIG. 3f,g ).
For example, a multifunctional RNA conjugate was recently constructed for specific delivery of an antimiR-21 therapeutic agent 140 (FIG. 3 g ). The conjugate combined antimiR-21 with an epidermal growth factor receptor (EGFR) aptamer as the targeting agent, a fluorescent dye (Alexa647) as an imaging agent and a three-way junction (3WJ) motif derived from bacteriophage ϕ29 packaging RNA (pRNA) as a molecular scaffold. Through a rational design and construction strategy, these components were efficiently assembled into a trifunctional RNA structure with an average hydrodynamic diameter of 15 nm, which had a long half-life (18.5 hours) and high thermostability. When administered systemically in a triple-negative breast cancer (TNBC)-bearing mouse model, the RNA nanoparticles specifically bound and were internalized into TNBC cells, suppressed miR-21, and resulted in efficient inhibition of tumour growth. Biodistribution studies in vivo indicated that the RNA nanoparticles specifically targeted tumours, with little or no accumulation in healthy organs or tissues.
Aptamer-drug conjugates. Chemical solid-phase synthesis of aptamers offers opportunities for covalent conjugation with small organic molecules, radiopharmaceuticals, polymers or even large proteins or enzymes (FIG. 3 h) . For example, the PSMA aptamer has been used to deliver a toxin into PSMA-overexpressing cells 141, 142 . The PSMA aptamer-toxin conjugates not only showed specific cell uptake into PSMA-positive cells but also decreased the toxicity of gelonin in non-targeted cells 141 . In addition, a dimeric PSMA DNA aptamer has been covalently conjugated with the antitumour chemotherapeutic drug doxorubicin through a pH-sensitive linkage 143 (FIG. 3i) . The resulting conjugates selectively delivered doxorubicin to PSMA-positive cells. Moreover, by taking advantage of the ability of this anthracycline drug to intercalate into the GC-rich helical strand of the aptamer, noncovalent aptamer-drug conjugates have also been formulated without using any chemical reaction. For example, multiple doxorubicin molecules were physically loaded into the double-stranded region of the PSMA RNA aptamer 144 (FIG. 3j) , and were selectively internalized by PSMA-positive cells, reducing cytotoxicity to PSMA-negative cells.
Similarly, target-specific radiopharmaceuticals have been developed by conjugating a radionuclide with a celltype-specific aptamer 145 . A nucleotide pre-labelled with a radionuclide can be directly incorporated into aptamers during enzymatic RNA transcription or chemical solid-phase synthesis 146 . Alternatively, through chemical solid-phase synthesis, desired functional groups (such as primary amines, sulfhydryls or carboxyls) can be precisely introduced into aptamers at a predefined position for covalent conjugation with a radionuclide, thus allowing more accurate and controllable conjugation than achieved with an antibody that generally contains multiple functional groups 147 . So far, there are many examples of radiolabelled aptamers for nuclear imaging and therapy. The most popularly used radionuclides include 99m Tc, 64 Cu, 68 Ga and 111 In. An initial example of an aptamer-radionuclide conjugate is an RNA aptamer targeting human tenascin-C, a large hexametric glycoprotein that is overexpressed in tumour stroma. A tenascin-C aptamer, TTA1 (REF. 148 ), was chemically modified with a primary amino group at its 5ʹ terminal end and subsequently conjugated with 99m Tc via a bifunctional chelator (2-mercaptoacetylglycylglycyl (MAG 2 )) 149 . In glioblastoma and breast cancer tumour xenografts, the resultant TTA1-99m Tc conjugate showed rapid tumour penetration and blood clearance, yielding a tumour/blood ratio of 50 within 3 hours. Moreover, aptamer uptake in several different human tumours was demonstrated to depend on the presence of the target tenascin-C protein. Although development efforts continue in this field, systemic in vivo evaluation of these systems is still lacking.
Aptamer-decorated nanomaterials as a drug delivery system. In addition to the examples above, in which an aptamer is directly conjugated to a therapeutic drug, celltype-specific aptamers are being exploited to 'decorate' nanocarriers carrying multiple cargoes. Several components are rationally assembled in one nanoscale carrier to achieve a multifunctional nanomedicine 150 . This may include a therapeutic agent (for example, therapeutic oligonucleotides or chemotherapy agents), an actively targeting agent (for example, cell-type-specific targeting aptamers) and an imaging component (for example, fluorescent dyes or radioactive agents) (FIG. 4) . Since the first example of a PSMA aptamer-nanoparticle bioconjugate for targeted delivery of rhodamine-labelled dextran Figure 3 | Schematics of cell type-specific RNA aptamers used as delivery agents. a | A chimaera composed of an aptamer and a small interfering RNA (siRNA) or microRNA (miRNA). The chimaera is synthesized as two pieces followed by an annealing step to make the chimeric RNA molecule. b | An aptamer-shRNA (short hairpin RNA) chimaera synthesized as one piece. c | An aptamer-streptavidin-siRNA conjugate. The siRNA and prostate-specific membrane antigen (PSMA) RNA aptamers are chemically conjugated with a biotin group. Then the two biotinylated siRNAs and two aptamers are non-covalently assembled via a streptavidin connector. d | The bispecific PSMA-4-1BB aptamer conjugate. The PSMA RNA aptamer and a bivalent 4-1BB RNA aptamer are tethered to complementary linker sequences and hybridized through Watson-Crick base pairing. e | An aptamer-sticky bridge-siRNA/miRNA conjugate. The aptamer and siRNA or miRNA are appended to complementary GC-rich bridge sequences and annealed by simple mixing that allows Watson-Crick base pairing. f | An aptamer-sticky bridge-antimiR conjugate. The single or multiple antimiR oligonucleotides are hybridized with the aptamers via a GC-rich sticky bridge. g | The 3WJ-aptamer-antimiR RNA conjugate contains an epidermal growth factor receptor (EGFR) aptamer as a targeting agent, an antimiR-21 sequence as a therapeutic agent, a fluorescent dye (Alexa647) as an imaging agent, and a three-way junction (3WJ) motif as a molecular scaffold. h | An aptamer-protein conjugate. Chemical synthesis incorporates a primary amino group at the 5ʹ end of the PSMA aptamer, allowing chemical modification with a crosslinker agent (N-succinimidyl 3-[2-pyridyldithio]-propionate (SPDP)), and subsequent conjugation with the cysteine residue of gelonin toxin through a disulfide linkage. i | An aptamer-anticancer drug conjugate. It is made by using an acid-labile acylhydrazone linkage or formaldehyde linkage. j | Physical conjugation between an aptamer and anthracycline drug (doxorubicin) through intercalation. 
Plekho1
(Pleckstrin homology domain-containing family O member 1). Has a role in the regulation of the actin cytoskeleton through its interactions with actin capping protein.
was reported in 2004 (REF. 151 ), various nanomaterials (including gold nanoparticles, iron oxide nanoparticles, single-walled carbon nanotubes, quantum dots, liposomes, micelles, dendrimers, branched polymers, proteins or viral capsids) have been assembled with cell-type-specific aptamers. A recent proof-of-concept study generated aptamer-functionalized lipid nanoparticles (LNPs) for siRNA delivery 152 . By using cell-based SELEX, DNA aptamers targeting both rat and human osteoblasts were selected and used for decoration of LNPs that encapsulated osteogenic Plekho1 (pleckstrin homology domain-containing family O member 1) siRNAs. The aptamer-LNP-siRNA delivery system not only facilitated in vivo osteoblast-selective siRNA uptake (mainly via micropinocytosis) but also resulted in osteoblast-specific Plekho1 gene silencing in vivo, consequently promoting bone formation and bone microarchitecture, and enhancing mechanical properties in both osteopaenic and healthy rodents. These proof-of-concept studies of aptamer-based nanomedicine provide continuing impetus for the development and clinical evaluation of therapeutic aptamers in the future.
Clinical development of aptamer therapeutics
To date, the FDA has approved one RNA aptamer, and ten aptamers have undergone clinical trials for the treatment of various conditions, including macular degeneration, coagulation, oncology and inflammation (TABLE 2) . As indicated above, all aptamers that have entered clinical trials so far act as antagonists.
Macular degeneration
There are three aptamers designated for use in ophthalmology 107 , including one approved drug (Macugen), and two in late-stage development (ARC-1905 and E-10030). They were raised from three different target proteins, respectively: VEGF, complement component 5 (C5) and platelet-derived growth factor (PDGF).
VEGF has an important role in neuronal development and maintenance within the central nervous system, including in the neural retina 17 . It is a therapeutic target for combating ocular vascular diseases: VEGF blockade reduces the growth of blood vessels and controls vascular leakage and swelling in the eye, which would otherwise lead to loss of central vision 16, 153 . Pegaptanib is a 27-nucleotide, pegylated, modified RNA aptamer that specifically binds to the major pathological VEGF isoform (extracellular VEGF 165 ), inhibits binding of VEGF to its receptors and, thus, prevents VEGF from stimulating blood vessel growth 14, 15, 154 . In 1993, the first attempt to develop VEGF aptamers started with a purified protein-based SELEX approach 155 , and identified unmodified RNA aptamers with low nanomolar affinity. To improve nuclease stability 156 , 2ʹ-aminopyrimidines were introduced into the initial library 157 . The 2ʹ-amino bases were subsequently substituted with 2ʹ-fluoro bases 68 , and a novel set of inhibitory RNA aptamers with improved nuclease resistance and picomolar affinity for VEGF were identified, including the pegaptanib prototype, clone t44. As a result of its superior performance as an inhibitor of VEGF receptor binding and vascular permeability, clone t44 was selected for clinical translation. Additional modifications, including 2ʹ-methoxypurine, the 3ʹ-3ʹ inverted deoxythymidine (idT) cap and 5ʹ-PEG conjugation (40 kDa) 158, 159 , were incorporated to further improve inhibitory activity and plasma half-life in vivo 88, 89 . In 2004, the FDA approved Macugen (pegaptanib sodium) as the world's first therapeutic aptamer and first RNA drug for the treatment of neovascular (wet) age-related macular degeneration (AMD). Macugen is administered by ophthalmic intravitreous injection every 6 weeks. However, pegaptanib has been largely supplanted by its Figure 4 | Cell-type-specific aptamer-functionalized nanocarriers for targeted therapy. Multiple components such as therapeutics (therapeutic oligonucleotides and chemotherapy agents), actively targeting agents (cell-type-specific aptamers) and imaging agents (fluorescent dyes or radioactivity agents) are rationally assembled into one nanoscale carrier to achieve multifunctional nanomedicine. Upon binding of the aptamer portion of the nanocarrier conjugate to the target receptor on the cell surface (step 1), the conjugate is internalized into cells (step 2), probably through a receptor-mediated endocytosis pathway. It is presumed that the conjugate shuttles into the endosome (step 3); subsequently, the therapeutic agents dissociate from the complex and escape the endosome. The released therapeutic agents mediate therapeutic function. siRNA, small interfering RNA.
ARC-1905
A modified RNA aptamer targeting complement 5 (C5) protein that has undergone clinical trials for the treatment of dry age-related macular degeneration.
E-10030
A modified DNA aptamer targeting platelet-derived growth factor (PDGF) that has undergone clinical trials for wet age-related macular degeneration therapy.
Aflibercept
Trade name Eylea; a recombinant fusion protein inhibitor of vascular endothelial growth factor (VEGF), and an approved biopharmaceutical drug for the treatment of wet age-related macular degeneration.
von Willebrand factor protein-based competitors, the monoclonal antibodies bevacizumab 160 and ranibizumab 161, 162 , as well as the recombinant fusion protein aflibercept (Eylea; Regeneron Pharmaceuticals) 163 . Although these antibodies bind to all isoforms of VEGF and are more beneficial than pegaptanib for BCVA (best corrected visual acuity) improvement, it has been reported that blocking all VEGF activity may increase the risk of hypertension and other adverse effects 164, 165 . To improve benefits while limiting such risks, pegaptanib may be combined with other drugs as an adjuvant agent for long-term treatment.
Another potential approach to treat AMD involves targeting of the complement system, which has important roles in retinal biology and AMD pathogenesis 166 In vitro and animal studies have demonstrated that PDGF is also a potential therapeutic target in the treatment of AMD 171 , in particular when it is combined with anti-VEGF therapies 172, 173 . E-10030, an aptamer originally derived from an in vitro DNA SELEX experiment, targets PDGF [174] [175] [176] . The selected aptamer, which specifically inhibited the binding of the PDGF subunit B homodimer to the pericyte cell surface receptor PDGFβ, was chemically modified, resulting in a 29-nucleotide modified DNA aptamer that showed no loss of binding affinity, and a 13-fold longer half-life in plasma than the unmodified DNA aptamer 177 . In a randomized phase IIb clinical trial investigating the safety and efficacy of E-10030 for wet AMD therapy, intravitreous injection of E-10030 in combination with anti-VEGF monotherapy (ranibizumab) (ClinicalTrials.gov identifier NCT01089517) 178 exhibited a favourable safety profile and improved BCVA, representing a 62% comparative benefit from the baseline (see the "Fovista (anti-PDGF) therapy fact sheet" on the Ophthotech website Ultimately, the combination of C5 or PDGF inhibitory aptamers with anti-VEGF monotherapy may be a promising therapeutic modality.
Coagulation
Four aptamers are currently being clinically evaluated for coagulation therapy. The aptamer-based anticoagulation system, REG1 (Regado Biosciences), comprises a 37-nucleotide modified aptamer (RB006) and a 17-nucleo tide antidote oligonucleotide (RB007). RB006 is an inhibitory RNA aptamer targeted to coagulation factor IXa, a proximal driver of clot formation 182 . Starting with a 2ʹ-fluoropyrimidine-modified RNA library, in vitro SELEX was performed against factor IXa, identifying the original aptamer (9.3) with the highest affinity 183 ; further truncation and modifications led to RB006. RB007 is a complementary antidote sequence that specifically binds to RB006 and rapidly reverses the anti-factor IXa activity of RB006 in a dose-dependent manner, allowing fine-tuning of the system. In preclinical studies, RB006 prevented arterial thrombosis with less bleeding than with heparin, the current standard of care. The ability to rapidly reverse aptamer function by treatment with a complementary oligonucleotide is an important and underappreciated attribute of these macromolecules. The results from phase I and II studies [184] [185] [186] [187] (REF. 190 )) indicate that the REG1 system is well tolerated in patients. Bolus administration is feasible and controllable for anticoagulation and reversal in subjects with coronary artery disease or acute coronary syndrome during percutaneous coronary intervention (PCI) and cardiac catheterization.
Recently, Regado conducted a large-scale, randomized comparison of REG1 with bivalirudin, a specific and reversible direct thrombin inhibitor (DTI), in patients undergoing PCI (ClinicalTrials.gov identifier NCT01848106 (REF. 191) ). However, this trial was terminated prematurely owing to an unacceptable risk of severe allergic reactions associated with the current formulation of REG1 (REFS 18, 99) . In addition, there was no evidence that REG1 reduced ischaemic events or bleeding complications compared with bivalirudin.
ARC-1779 is a 39-nucleotide modified DNA aptamer that specifically recognizes the A1 domain of von Willebrand factor (vWF). vWF has a central role in primary haemostasis by mediating platelet adhesion to damaged vascular subendothelium and subsequent platelet aggregation 192 . ARC-1779 was originally generated from a DNA library via SELEX, and then subjected to truncation and modifications to obtain an optimized, In contrast to therapeutic aptamers that are modified for increased nuclease resistance and prolonged halflife in vivo, NU172 is a 26-nucleotide unmodified DNA aptamer. NU172 was selected against thrombin 199 and induces a short-acting anticoagulation effect. Originally identified through DNA SELEX, a truncated version was created for clinical study. In a phase Ib proof-of-concept trial, NU172 was well tolerated without serious adverse responses, and rapidly elicited and maintained anticoagulation with a rapid return towards the baseline after the infusion ended, suggesting that it has the potential to be rapidly reversed without the need for an antidote (see the NU172 annual report on the wikinvest website). ARCA Biopharma initiated a phase II clinical trial to evaluate the therapeutic efficacy of NU172 in patients under going coronary artery bypass grafting surgery with median sternotomy (ClinicalTrials.gov identifier NCT00808964 (REF. 200) ), but the current status of this study is unknown.
Unlike the previous aptamers that target the intrinsic coagulation pathway, ARC19499 is a 32-nucleotide modified RNA aptamer that targets tissue factor pathway inhibitor (TFPI), the negative regulator of factor VIIa in the extrinsic tissue factor coagulation pathway 201 . The parent clone was originally isolated from a modified RNA library via in vitro selection; ARC19499 was generated from truncated clone variants with additional chemical modifications. By specifically inhibiting TFPI, ARC19499 enables clot initiation and propagation, thus mediating a procoagulant haemostatic effect 202 . In 2010, a phase I study was started to evaluate the safety and efficacy of ARC19499 in individuals with haemophilia, but it was terminated without further updates (ClinicalTrials.gov identifier NCT01191372 (REF. 203)).
Oncology
One DNA aptamer (AS1411) and one L-form RNA aptamer (NOX-A12) have undergone clinical trials for the treatment of cancers. AS1411, formerly named ARGO100, is a 26-nucleotide G-quadruplex DNA oligonucleotide (which was not evolved by classic SELEX 204 ) and is the first aptamer in clinical trials for the treatment of human cancer. It was originally generated from a screen of antisense oligonucleotides with antiproliferative function, then pegylated to prolong its half-life for in vivo applications. Owing to its G-quadruplex structures, AS1411 is resistant to nuclease degradation. AS1411 shows high affinity to the external domain of nucleolin 205, 206 , which is a BCL2-mRNA-binding protein involved in cell survival, growth and proliferation, and is overexpressed on the surface of tumour cells 207 . After binding to nucleolin, AS1411 is rapidly internalized and destabilizes BCL2 mRNA, probably leading to the induction of apoptosis. AS1411 can function as a tumour-targeting agent and as a promising anticancer agent 208 . It inhibited cancer in various preclinical models 209 , including breast, renal and lung cancer, and in 2007 it was reported to be well tolerated without serious side effects in an open-label phase I study in advanced solid tumours 210 (ClinicalTrials.gov identifier NCT00881244 (REF. 211)) . In 2009, a phase II trial assessed the efficacy and safety of AS1411 combined with cytarabine, an anticancer chemotherapy drug, for the treatment of patients with primary refractory or relapsed acute myeloid leukaemia (AML) (ClinicalTrials.gov identifier NCT00512083 (REF. 212)). However, a subsequent phase II trial for renal cell carcinoma showed that AS1411 had minimal activity in unselected patients (ClinicalTrials.gov identifier NCT00740441 (REF. 213)). Only one patient with mutations in fibroblast growth factor receptor 2 (FGFR2) and mechanistic target of rapamycin (mTOR) showed an excellent response, implying that future efforts may benefit from the discovery of predictive biomarkers of response to AS1411 therapy.
NOX-A12 (REFS 214, 215) is a 45-nucleotide L-form RNA aptamer known as a Spiegelmer, developed against chemokine C-X-C motif ligand 12 (CXCL12). Also known as stromal cell-derived factor 1 (SDF1) [216] [217] [218] , CXCL12 has an important role in tumour proliferation, new blood vessel formation and metastasis. It has two types of binding sites, both of which are targets of therapeutic intervention. By binding to these two key sites, NOX-A12 disrupts CXCL12 activity and modulates the tumour microenvironment to fight tumours, including multiple myeloma and solid tumours (lung, colorectal and brain cancer). NOX-A12 was developed by NOXXON 
Inflammation
Two anti-inflammatory aptamers (NOX-E36 and NOX-H94) are under clinical development for the treatment of diabetic nephropathy and anaemia of chronic disease, respectively. Like NOX-A12, they are pegylated C5a, complement component 5a; CCL2, chemokine C-C motif ligand 2; CGRP, calcitonin gene-related peptide; CXCL12, chemokine C-X-C motif ligand 12; ELASA, enzyme-linked apta-sorbent assay; ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; HTSA, high-throughput screening assay; PDGF, platelet-derived growth factor; SELEX, systematic evolution of ligands by exponential enrichment; SOMAmer, slow off-rate modified aptamer; SPR, surface plasmon resonance; TFPI, tissue factor pathway inhibitor. L-form RNA aptamers generated through Spiegelmer technology by NOXXON. The 40-nucleotide aptamer NOX-E36 (REFS 74, (223) (224) (225) binds to human chemo kine C-C motif ligand 2 (CCL2; also known as MCP1), and can specifically inhibit the activity of the chemo kine, thereby preventing infiltration of pro-inflammatory cells into the kidney. CCL2 has a key role in modulating migration and infiltration of monocytes and macrophages, and it is overexpressed in several inflammatory diseases 217 . Evaluation of phase I and II clinical trials conducted in patients with diabetic nephropathy showed that NOX-E36 was safe and well tolerated, and showed promising efficacy for at least 12 weeks after termination of treatment (see NOXXON product candidates: NOX-E36) (ClinicalTrials.gov identifiers NCT01085292 (REF. 226) and NCT01547897 (REF. 227)) .
The 44-nucleotide L-form RNA aptamer NOX-H94 binds to human hepcidin, which is a regulator of iron metabolism 228 , thereby blocking hepcidin-induced ferroportin degradation and ferritin expression. Inhibition of hepcidin has therapeutic benefit in anaemia of chronic inflammation 229 . In a pharmacodynamics study with healthy individuals (ClinicalTrials.gov identifier NCT01372137 (REF. 230)), NOX-H94 blocked hepcidin-mediated effects on serum iron levels (see NOXXON product candidates: NOX-H94). Recently, two phase II evaluations were completed for NOX-H94 in patients with cancer-associated anaemia and in dialysis patients with ESA (erythropoiesis-simulating agent)-hyporesponsive anaemia (ClinicalTrials.gov identifiers NCT01691040 (REF. 231) and NCT02079896 (REF. 232), respectively). Treatment with NOX-H94 induces an increase in haemoglobin levels, suggesting that hepcidin inhibition may also be an effective target for the treatment of cancerassociated anaemia with functional iron deficiency.
Conclusions
The current paucity of commercial success with aptamerbased products may be due to several factors. Early exclusive intellectual property protection for SELEX technology limited initial distribution. In addition, in contrast to antibodies, which have a well-developed commercial infrastructure, the development pathway for aptamers, the education and investment required, and related knowledge (for example, medicinal formulation, pharmacokinetic and pharmacodynamic properties and toxicity) are all insufficient. Furthermore, challenges associated with the design and formulation of RNAbased therapeutics still exist. Overcoming these challenges and taking full advantage of the unique attributes of aptamers is vital for the future success of aptamers as therapeutics.
Despite the limited commercial success with aptamerbased therapeutics, the lessons learned from previous failures and successful technological advancements are valuable for informing us of future opportunities for aptamer-based therapeutics. Proof-of-concept studies in aptamer technology continue to reveal their promising functionality and vast therapeutic potential. As a unique class of biomolecules, aptamers not only possess the flexibility of small molecules -allowing them to contact binding sites that may not be accessible to larger antibodies -but also possess the high specificity of antibodies, allowing targeted disease therapy that cannot be achieved with small drug molecules. These unique advantages of aptamers could fill a niche market, such as bacterial and viral treatment, cancer immunotherapy, antitoxins or targeted delivery. For example, rapid aptamer selection technology has the potential to keep up with viral emergence and mutation, and could fill the absence of fast-track vaccines. In addition, the ability of many aptamers to internalize upon binding to cellular receptors, in a cell-specific manner, is likely to improve the targeting specificity and pharmaco kinetic profile of the nanocarrier, resulting in synergistic therapeutic effects when two or more therapeutic agents are administered simultaneously in a combinatorial therapy format.
The aptamer field has probably touched only the tip of the iceberg. As more researchers devote themselves to rational aptamer development, next-generation aptamerbased therapeutics with superior biological functions and pharmacokinetic profiles are highly anticipated. Furthermore, factors such as the market demand for cost-effective treatments, technological advancements in synthesis and formulation, and expiration of the SELEX patent, provide a strong impetus for the development of this promising class of therapeutics.
